ESCRS - FP09.02 - First Clinical Results Of A Multicentric Prospective Study On The Visual Performance Of Patients Implanted With A Hydrophobic Trifocal Iol

First Clinical Results Of A Multicentric Prospective Study On The Visual Performance Of Patients Implanted With A Hydrophobic Trifocal Iol

Published 2024 - 42nd Congress of the ESCRS

Reference: FP09.02 | Type: Free paper | DOI: 10.82333/0g66-bc10

Authors: Gerd Uwe Auffarth 1 , Florian Kretz 2 , Pedro T Rivero 3 , Ramin Khoramnia* 4

1Ophthalmology,University Eye Clinic Heidelberg,Heidelberg,Germany, 2Precise Vision Augenärzte,Rheine,Germany, 3Oftalvist ,Alicante,Spain, 4University Eye Clinic Heidelberg,University Eye Clinic Heidelberg,Heidelberg,Germany

Purpose

To determine the postoperative visual performance of patients after bilateral implantation of the Zeiss AT ELANA 841P lens, a new hydrophobic trifocal intraocular lens (IOL).

Setting

Universitäts-Augenklinik Heidelberg, Germany; Precise Vision Augenärzte, Rheine, Germany; Oftalvist Alicante, Spain

Methods

This ongoing prospective, multicentric clinical trial includes a total of 87 patients scheduled for bilateral implantation of the AT ELANA 841P (Carl Zeiss Meditec AG, Jena, Germany) IOL following cataract or refractive lens exchange surgery. Follow-up visits are scheduled for 1-month, 3-months, and 12-months and include: monocular and binocular uncorrected and distance-corrected visual acuities (VA) for far (UDVA, CDVA), intermediate (UIVA, DCIVA), and near (UNVA, DCNVA), subjective refraction, monocular and binocular defocus curve, photopic and mesopic contrast sensitivity, patient satisfaction in terms of visual disturbance and spectacle independence, and the evaluation of posterior capsule opacification.

Results

To date, 1-month results from 6 eyes (3 patients) are available. Postoperatively, mean binocular uncorrected logMAR VAs were -0.08±0.03 (UDVA), 0.08±0.11 (UIVA 80 cm), 0.11±0.08 (UIVA 66 cm), and 0.18±0.10 (UNVA 40 cm, UNVA at preferred distance). Mean binocular distance-corrected logMAR VAs were -0.10±0.02 (CDVA), 0.08±0.11 (DCIVA 80 cm), 0.11±0.08 (DCIVA 66 cm), 0.15±0.12 (DCNVA 40 cm), and 0.14±0.11 (DCNVA at preferred distance). Mean manifest spherical equivalent was 0.11±0.42 D at 1 month, with 67% of eyes within ±0.25 D, and 100% within ±0.75 of the refractive target. For all patients, the binocular photopic defocus curve showed a wide range of functional vision (CDVA of 0.2 logMAR or better) from distance to 33 cm

Conclusions

The continued development of the AT LISA tri lens design resulted in a new IOL model called AT ELANA 841P. This is a hydrophobic, aberration-neutral, C-loop haptic lens with a full trifocal optic design. Our initial results from this study are promising and indicate that the AT ELANA 841P IOL allows full restoration of uncorrected vision over a wide range of distances and is a safe, predictable, and effective treatment option in the course of cataract or refractive lens exchange surgery. Postoperative results regarding rates of spectacle freedom, photic phenomena and overall patient satisfaction are still pending. Data on more eyes over a longer follow-up period will be presented at the conference.